At a glance
ClinicalIndex Comparison Record- ✓Histologically proven renal cell carcinoma with clinical presentation consistent with metastatic disease
- ✓Bidimensionally measurable disease by conventional imaging
- ✓Off chemotherapy or immunotherapy for at least 6 weeks prior to study entry
- ✓Karnofsky Performance Status at least 70
- ✕Significant prior radiation therapy to the entire pelvis and/or lumbosacral spine
- ✕Clinically significant cardiac disease
- ✕Serious infection requiring antibiotic treatment or other serious illness
- ✕Central Nervous System (CNS) tumor involvement
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Study of 131I-Labeled Chimeric Antibody G250 (131I-cG250) in Patients With Advanced Renal Carcinoma
In Brief
A Phase 2 clinical trial evaluating Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250) for Kidney Cancer. Completed, enrolled 15 participants across 1 site.
Detailed Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients with advanced kidney cancer.
Study Details
Timeline
Interventions
cG250 is an IgG1 chimeric monoclonal antibody. It was supplied as a sterile solution at a concentration of 1.0 mg/mL in either a 2 mL or a 5 mL vial. cG250 was radiolabeled with Iodine-131 prior to use.